Stem Cell Therapeutics Announces Results of Annual Shareholders Meeting
May 28 2014 - 8:45AM
Marketwired
Stem Cell Therapeutics Announces Results of Annual Shareholders
Meeting
TORONTO, ONTARIO--(Marketwired - May 28, 2014) - Stem Cell
Therapeutics Corp. ("SCT") (TSX:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing innovative therapies for the
treatment of cancer, today announced that the company's annual and
special meeting of shareholders held yesterday voted to support all
of the resolutions proposed to shareholders.
Each of the seven
proposed directors was elected: Dr. Calvin Stiller, Mr. Luke
Beshar, Dr. Henry Friesen, Dr. Robert Kirkman, Dr. Michael Moore,
Dr. Thomas Reynolds and Dr. Niclas Stiernholm. The shareholders
also voted to approve the company's amended and restated stock
option, deferred share unit and shareholder rights plans.
Shareholders also
supported the change of the company's name to Trillium Therapeutics
Inc., the approval of two administrative by-law resolutions, and
agreed to provide the Board of Directors with the authority to
consolidate the outstanding common shares.
About Stem Cell
Therapeutics:
Stem Cell
Therapeutics Corp. is an immuno-oncology company developing
innovative therapies for the treatment of cancer. The Company has
two premier preclinical programs, SIRPaFc and a CD200 monoclonal
antibody (mAb), which target two key immunoregulatory pathways that
tumor cells exploit to evade the host immune system. SIRPaFc is an
antibody-like fusion protein that blocks the activity of CD47, a
molecule that is upregulated on cancer stem cells in AML and
several other tumors. The CD200 mAb is a fully human monoclonal
antibody that blocks the activity of CD200, an immunosuppressive
molecule that is overexpressed by many hematopoietic and solid
tumors. SCT's clinical stage programs include tigecycline which is
being evaluated in a multi-centre Phase I study in patients with
acute myeloid leukemia (AML), and TTI-1612 that has completed a
28-patient Phase I trial in interstitial cystitis ("IC") patients.
For more information, visit: www.stemcellthera.com
Caution Regarding
Forward-Looking Information:
This press release
may contain forward-looking statements, which reflect SCT's current
expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include changing market
conditions; the successful and timely completion of pre-clinical
and clinical studies; the establishment of corporate alliances; the
impact of competitive products and pricing; new product development
risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at
standards acceptable to health regulatory authorities to complete
clinical trials or to meet commercial demand; and other risks
detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Neither TSX nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX) accepts responsibility for the adequacy or
accuracy of this release.
Stem Cell Therapeutics Corp.James ParsonsChief Financial
Officer+1 416 595
0627jparsons@stemcellthera.comwww.stemcellthera.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Sep 2023 to Sep 2024